Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst
The FDA’s recommendation against adding seven peptides to the 503A Bulk List weighs on Hims & Hers Health Inc ‘s (NYSE: HIMS ) peptide optionality narrative, BofA Securities said. Analyst Allen Lutz maintained a Neutral rating while raising the price target to $36 from $25. The FDA released briefing materials this week